QPS Hepatic Biosciences Scientists Co-author Article on the Interpretation of the Pre-Clinical Liver Effects Seen with a New Chemical Entity - August, 2014

NP260 was designed as a first-in-class selective antagonist of α4-subtype GABAA receptors and exhibited promising efficacy in animal models for pain, epilepsy, psychosis, and anxiety. However, development of NP260 was complicated by a 28-day safety study in dogs in which pronounced elevations of serum aminotransferase were observed, despite the lack of accompanying histopathological evidence of hepatocellular injury.

To investigate the liver effects of NP260, a diagnostic biomarker approach, coupled with sensitive in vitro screening strategies, was implemented to help clarify the compound’s toxicity potential.

20 years in pharma R&D navigation